Reduction of parasite levels in blood improves pregnancy outcome during experimental Trypanosoma cruzi infection

Parasitology

Volumn 136, Issue 6, 2009, Pages 627-639

  Solana, M E ^a   Alba Soto, C D ^a   Fernandez M C ^a   Poncini, C V ^a   Postan, M ^b   Gonzalez Cappa S M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

Author keywords

Activation memory markers; Benznidazole; Fetal resorption; IgG isotypes; LT phenotypic analysis; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; CD69 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; CD44 PROTEIN, MOUSE; HERMES ANTIGEN; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; NITROIMIDAZOLE DERIVATIVE; PROTOZOON ANTIBODY; T LYMPHOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CHAGAS DISEASE; CONTROLLED STUDY; FEMALE; FERTILITY; FETUS RESORPTION; HISTOPATHOLOGY; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; NONHUMAN; PARASITEMIA; PHENOTYPE; PLACENTA; PREGNANCY OUTCOME; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRYPANOSOMA CRUZI; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; CYTOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PARASITOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; SPLEEN; TIME;

MUS; TRYPANOSOMA CRUZI;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; NITROIMIDAZOLES; PARASITEMIA; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREGNANCY OUTCOME; SPLEEN; TIME FACTORS; TRYPANOSOMA CRUZI;

EID: 67651171608     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182009005770     Document Type: Article

References (46)

1. Ahmed, R. and Gray, D. (1996). Immunological memory and protective immunity: understanding their relation. Science 272, 54-60. doi: 10.1126/science.272.5258.54. (Pubitemid 26110754)
2. Añez, N., Carrasco, H., Parada, H., Crisante, G., Rojas, A., Fuenmayor, C., Gonzalez, N., Percoco, G., Borges, R., Guevara, P. and Ramirez, J. L. (1999). Myocardial parasite persistence in chronic chagasic patients. American Journal of Tropical Medicine and Hygiene 60, 726-732. (Pubitemid 29233071)
3. Bertocchi, G. L., Álvarez, M. G., Pérez, D., Armenti, A., Viotti, R. J., Lococo, B., Petti, M., Postan, M., Albareda, M. C., Laucella, S. A. and Tarleton, R. L. (2008). Evaluación inmunológica del tratamiento con benznidazol en la enfermedad de Chagas crónica. Revista Argentina de Cardiología 76, 260-265.
4. Burgos, J. M., Altcheh, J., Bisio, M., Duffy, T., Valadares, H. M., Seidenstein, M. E., Piccinali, R., Freitas, J. M., Levin, M. J., Macchi, L., Macedo, A. M., Freilij, H. and Schijman, A. G. (2007). Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas' disease. International Journal for Parasitology 37, 1319-1327. doi: 10.1016/j.ijpara.2007.04.015. (Pubitemid 47285110)
5. Bustamante, J. M., Bixby, L. M. and Tarleton, R. L. (2008). Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas' disease. Nature Medicine 14, 542-550. doi: 10.1038/nm1744.
6. Cardillo, F., Postol, E., Nihei, J., Aroeira, L. S., Nomizo, A. and Mengel, J. (2007). B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection. Immunology 122, 584-595. doi:10.1111/J.1365-2567.2007.02677-x (Pubitemid 350075957)
7. Dos Reis, G. (1997). Cell-mediated immunity in experimental Trypanosoma cruzi infection. Parasitology Today 13, 335-342. doi:10.1016/S0169-4758(97) 01073-9.
8. Freilij, H., Muller, L. and González Cappa, S. M. (1983). Direct micromethod for diagnosis of acute and congenital Chagas' disease. Journal of Clinical Microbiology 18, 327-330.
9. Garcia, S., Ramos, C. O., Senra, J. F., Vilas-Boas, F., Rodrigues, M. M., Campos-de-Carvalho, A. C., Ribeiro-dos-Santos, R. and Soares, M. B. (2005). Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49, 1521-1528. doi: 10.1128/AAC.49.4.1521-1528.2005. (Pubitemid 40463384)
10. Gazzinelli, R., Pereira, M. E., Romanha, A., Gazzinelli, G. and Brener, Z. (1991). Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunology 13, 345-356. doi:10.1111/j.1365-3024.1991.tb00288.x
11. González Cappa, S. M., Chiale, P., Del Prado, G. E., Katzin, A. M., Martín, G. W., Isola, E. L. D., Abramo Obrego, L. A. and Segura, E. L. (1980). Aislamiento de una cepa de T. cruzi de un paciente con miocardiopatía chagásica crónica y su caracterizació n biológica. Medicina (Buenos Aires) (Suppl. 1) 40, 63-68.
12. Hernandez-Matheson, I. M., Frankowski, R. F. and Held, B. (1983). Foeto-maternal morbidity in the presence of antibodies to Trypanosoma cruzi. Transactions of the Royal Society of Tropical Medicine and Hygiene 77, 405-411.
13. Higo, H., Miura, S., Horio, M., Mimori, M., Hamano, S., Agatsuma, T., Yanagi, T., Cruz-Reyes, A., Uyema, N., Rojas de Arias, A., Matta, V., Akahane, H., Hirayama, K., Takeuchi, T., Tada, I. and Himeno, K. (2004). Genotypic variation among lineages of Trypanosoma cruzi and its geographic aspects. Parasitology International 53, 337-344. doi: 10.1016/j.parint.2004.06.001 (Pubitemid 39303615)
14. Kalia, V., Sarkar, S., Gourley, T. S., Rouse, B. T. and Ahmed, R. (2006). Differentiation of memory B and T cells. Current Opinion in Immunology 18, 255-264. doi: 10.1016/j.coi.2006.03.020.
15. Krautz, G. M., Kissinger, J. C. and Krettli, A. U. (2000). The targets of the lytic antibody response against Trypanosoma cruzi. Parasitology Today 16, 31-34. doi: 10.1016/S0169-4758(99)01581-1.
16. Marcet, P. L., Duffy, T., Cardinal, M. V., Burgos, J. M., Lauricella, M. A., Levin, M. J., Kitron, U., Gürtler, R. E. and Schijman, A. G. (2006). PCR-based screening and lineage identification of Trypanosoma cruzi directly from faecal samples of triatomine bugs from northwestern Argentina. Parasitology 132, 57-65. doi:10.1017/S0031182005008772. (Pubitemid 43053661)
17. Marinho, C. R., D'Imperio Lima, M. R., Grisotto, M. G. and Alvarez, J. M. (1999). Influence of acutephase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infection and Immunity 67, 308-318.
18. Marinho, C. R. F., Nuñez-Apaza, L. N., Martins-Santos, R., Bastos, K. R. B., Bombeiro, A. L., Bucci, D. Z., Sardinha, L. R., Lima, M. R. D. and Álvarez, J. M. (2007). IFN-γ, but not nitric oxide or specific IgG, is essential for the in vivo control of lowvirulence Sylvio X10/4 Trypanosoma cruzi parasites. Scandinavian Journal of Immunology 66, 297-308. doi:10.1111/j.1365-3083.2007.01958.x
19. Marin-Neto, J. A., Cunha-Neto, E., Maciel, B. C. and Simões, M. V. (2007). Pathogenesis of Chronic Chagas Heart Disease. Circulation 115, 1109-1123. doi: 10.1161/CIRCULATIONAHA.106.624296. (Pubitemid 46679556)
20. Martins-Filho, O., Pereira, M. E. S., Carvalho, J. F., Cançado, J. R. and Brener, Z. (1995). Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 2, 569-573.
21. Martins-Filho, O. A., Eloi-Santos, S. M., Teixeira Carvalho, A., Oliveira, R. C., Rassi, A., Luquetti, A. O., Rassi, G. G. and Brener, Z. (2002). Doubleblind study to evaluate flow cytometry analysis of antilive trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 9, 1107-1113. doi:10.1128/CDLI.9.5.1107-1113.2002. (Pubitemid 34988483)
22. Maya, J. D., Cassels, B. K., Iturriaga-Vásquez, P., Ferreira, J., Faúndez, M., Galanti, N., Ferreira, A. and Morello, A. (2007). Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comparative Biochemistry and Physiology 146, 601-620. doi:10.1016/j.cbpa.2006.03.004. (Pubitemid 46341910)
23. Michailowsky, V., Murta, S. M. F., Carvalho- Oliveira, L., Pereira, M. E., Ferreira, L. R., Brener, Z., Romanha, A. J. and Gazzinelli, R. T. (1998). Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 42, 2549-2556. (Pubitemid 28462892)
24. Mirkin, G.A, Celentano, A. M., Malchiodi, E. L., Jones, M. and González Cappa, S. M. (1997). Different Trypanosoma cruzi strains promote neuromyopathic damage mediated by distinct T lymphocyte subsets. Clinical and Experimental Immunology 107, 328-334. doi: 10.1111/j.1365-2249.1997.267-ce1166. x.
25. Mjihdi, A., Lambot, M. A., Stewart, I. J., Detournay, O., Noë l, J. C., Carlier, Y. and Truyens, C. (2002). Acute Trypanosoma cruzi infection in mouse induces infertility or placental parasite invasion and ischemic necrosis associated with massive fetal loss. American Journal of Pathology 161, 673-680.
26. Murta, S. M., Ropert, C., Alves, R. O., Gazzinelli, R. T. and Romanha, A. J. (1999). In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population. Parasite Immunology 21, 535-544. doi: 10.1046/j.1365-3024.1999. 00251.x (Pubitemid 29457290)
27. Olivieri, B. P., Cotta-De-Almeida, V. and Araújo-Jorge, T. (2002). Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection. Antimicrobial Agents and Chemotherapy 46, 3790-3796. doi: 10.1128/AAC.46.12.3790-3796.2002.
28. Piaggio, E., Roggero, E., Pitashny, M., Wietzerbin, J., Bottasso, O. A. and Revelli, S. S. (2001). Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitology Research 87, 539-547. doi: 10.1007/s004360000357.
29. Risso, M. G., Garbarino, G. B., Mocetti, E, Campetella, O., Gonzalez Cappa, S. M., Buscaglia, C. A. and Leguizamon, M. S. (2004). Differential expression of a virulence factor, the transsialidase, by the main Trypanosoma cruzi phylogenetic lineages. Journal of Infectious Diseases 189, 2250-2259. doi: 10.1086/420831. (Pubitemid 38757198)
30. Rodriguez, A. M., Santero, F., Afchain, D., Bazin, H. and Capron, A. (1981). Trypanosoma cruzi infection in B-cell-deficient rats. Infection and Immunity 31, 524-529. (Pubitemid 11146223)
31. Romanha, A. J., Alves, R. O., Murta, S. M., Silva, J. S., Ropert, C. and Gazzinelli, R. T. (2002). Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-γ in mediating parasitologic cure. Journal of Infectious Diseases 186, 823-828. doi: 10.1086/342415 (Pubitemid 35013435)
32. Rozas, M., Botto-Mahan, C., Coronado, X., Ortiz, S., Cattan, P. E. and Solari, A. (2007). Coexistence of Trypanosoma cruzi genotypes in wild and periodomestic mammals in Chile. American Journal of Tropical Medicine and Hygiene 77, 647-653. (Pubitemid 351844286)
33. Sathler-Avelar, R., Vitelli-Avelar, D. M., Lima Massara, R., de Lana, M., Pinto Dias, J. C., Teixeira-Carvalho, A., Eloi-Santos, S. M. and Martins-Filho, O. A. (2008). Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes and Infection 10, 103-113. doi:10.1016/j.micinf.2007.10.009
34. Sathler-Avelar, R., Vitelli-Avelar, D. M., Massara, R. L., Borges, J. D., Lana, M., Teixeira-Carvalho, A., Dias, J. C., Elói-Santos, S. M. and Martins-Filho, O. A. (2006). Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scandinavian Journal of Immunology 64, 554-563. doi: 10.1111/j.1365-3083.2006.01843.x (Pubitemid 44536341)
35. Savino, W., Villa-Verde, D., Mendes-da-Cruz, D., Silva-Monteiro, E., Perez, A., Aoki, M. P., Bottasso, O., Guiñazú, N., Silva-Barbosa, S. and Gea, S. (2007). Cytokines and cell adhesion receptors in the regulation of immunity to Trypanosoma cruzi. Cytokine & Growth Factor Reviews 18, 107-124. doi:10.1016/j.cytogfr.2007.01.010. (Pubitemid 46401432)
36. Solana, M. E., Celentano, A. M., Tekiel, V. S., Jones, M. and González Cappa, S. M. (2002). Trypanosoma cruzi: effect of parasite subpopulations on murine pregnancy outcome. Journal of Parasitology 88, 102-106.
37. Steindel, M., Kramer Pacheco, L., Scholl, D., Soares, M., de Moraes, M. H., Eger, I., Kosmann, C., Sincero, T. C., Stoco, P. H., Murta, S. M., de Carvalho-Pinto, C. J. and Grisard, E. C. (2008). Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. Diagnostic Microbiology and Infectious Disease 60, 25-32. doi:10.1016/j. diagmicrobio.2007.07.016. (Pubitemid 350235169)
38. Sztein, M. B. and Kierszenbaum, F. (1992). Suppression by Trypanosoma cruzi of T-cell receptor expression by activated human lymphocytes. Immunology 77, 277-283.
39. Tarleton, R. L. (2001). Parasite persistence in the aetiology of Chagas disease. International Journal for Parasitology 31, 549-553. doi:10.1016/S0020-7519(01)00158-8.
40. Torrico, M. C., Solano, M., Guzmán, J. M., Parrado, R., Suarez, E., Alonzo-Vega, C., Truyens, C., Carlier, Y. and Torrico, F. (2005). Estimation of the parasitaemia in Trypanosoma cruzi human infection : high parasitaemias are associated with severe and fatal congenital Chagas disease. Revista da Sociedade Brasileira de Medicina Tropical 38 (Suppl. 2), 58-61.
41. Viotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M. G., Postan, M. and Armenti, A. (2006). Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Annals of Internal Medicine 144, 724-734. (Pubitemid 46780632)
42. Virreira, M., Serrano, G., Maldonado, L. and Svoboda, M. (2006). Trypanosoma cruzi: typing of genotype (sub)lineages in megacolon samples from bolivian patients. Acta Tropica 100, 252-255. doi:10.1016/j.actatropica.2006.11. 005 (Pubitemid 46176770)
43. Virreira, M., Truyens, C., Alonso-Vega, C., Brutus, L., Jijena, J., Torrico, F., Carlier, Y. and Svoboda, M. (2007). Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns. American Journal of Tropical Medicine and Hygiene 77, 102-106. (Pubitemid 351844359)
44. Vitelli-Avelar, D. M., Sathler-Avelar, R., Wendling, A. P., Rocha, R. D., Teixeira-Carvalho, A., Martins, N. E., Dias, J. C., Rassi, A., Luquetti, A. O., Elói-Santos, S. M. and Martins-Filho, O. A. (2007). Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory. Journal of Immunological Methods 318, 102-112. doi:10.1016/j.jim.2006.10.009. (Pubitemid 46026814)
45. World Health Organization (2002). Control of Chagas disease. WHO Technical Report Series No. 905. World Health Organization, Geneva, Switzerland.
46. Zhang, L. and Tarleton, R. L. (1999). Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. Journal of Infectious Diseases 180, 480-486. doi: 10.1086/314889.